Concordance Between Patient- and Physician-Reported Improvement With Dupilumab in Atopic Dermatitis

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Dupilumab is an FDA-approved biologic for moderate to severe atopic dermatitis (AD).
• Assessing concordance between patient and physician outcome assessments for dupilumab is crucial for understanding real-world effectiveness.
• Limited data exists on the alignment of patient-reported symptoms and physician-observed clinical improvements.

Purpose of the Study:

• To evaluate the concordance between patient-reported and physician-reported improvement in adults with moderate to severe atopic dermatitis treated with dupilumab.
• To analyze improvement patterns and treatment persistence over time in a real-world clinical setting.

Main Methods:

• Retrospective cohort study of 405 adults with moderate to severe atopic dermatitis initiating dupilumab (2017-2023).
• Abstracted physician notes for binary patient-reported and physician-reported improvement at predefined intervals post-initiation.
• Analyzed patient-physician concordance, improvement rates, and treatment persistence.

Main Results:

• High rates of patient-reported (89.1%) and physician-reported (81.6%) improvement were observed.
• Patient-physician concordance was high at 88.9%.
• Treatment persistence was 86.2% at 12 months and 73.1% at 36 months, with discontinuation reasons including inefficacy, adverse events, and clinical improvement.

Conclusions:

• Dupilumab demonstrates significant patient- and physician-reported efficacy in moderate to severe atopic dermatitis.
• High concordance between patient and physician assessments supports dupilumab's effectiveness in clinical practice.
• Sustained treatment persistence highlights the long-term benefits of dupilumab for atopic dermatitis management.